HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kompoliti, K. Articles by Raman, R. Search for Related Content PubMed PubMed Citation Articles by Kompoliti, K. Articles by Raman, R.

Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson’s disease

From the Section of Movement Disorders, Department of Neurological Sciences (Drs. Kompoliti and Goetz); the Department of Communication Disorders and Sciences (Dr. Wang); and the Department of Preventive Medicine (Dr. Leurgans and R. Raman), Rush-Presbyterian-St. Luke’s Medical Center, Rush University, Chicago, IL.

Address correspondence and reprint requests to Dr. Katie Kompoliti, Section of Movement Disorders, Department of Neurological Sciences, 1725 West Harrison, Suite #1106, Chicago, IL 60612; e-mail: kkompoli{at}rush.edu

OBJECTIVE: To determine the effect of central dopaminergic stimulation with apomorphine on speech in PD.

BACKGROUND: Most patients with PD have a speech disorder. Of those, 89% have involvement of laryngeal function, and 45% have additional articulatory dysfunction. The effect of dopaminergic medications on these two dimensions of speech impairment in PD has not been selectively studied.

METHODS: In a randomized, double-blind, placebo-controlled crossover design, patients with PD and speech impairment, Hoehn and Yahr stages 2 to 4 "off," and without severe dyskinesias were given placebo or apomorphine injections 0.05 mg/kg subcutaneously during two consecutive outpatient visits. They were pretreated with domperidone for 48 hours and were tested off their parkinsonian medications for 12 hours. Laryngeal function was assessed by maximum sustained vowel phonations and comfortable vowel phonations. Articulatory function was evaluated by speech intelligibility score, speaking rate, and efficiency ratio.

RESULTS: Ten patients, mean age 73.4 years (SD = 6.6), disease duration 8.7 years (SD = 6.3), were tested. The baseline motor score on the Unified Parkinson’s Disease Rating Scale (UPDRSm) and all experimental speech variables were equivalent on both placebo and apomorphine days. At a dose of apomorphine that provoked improvement in UPDRSm (p = 0.0078), no index of either laryngeal or articulatory function improved significantly after apomorphine administration.

CONCLUSION: Laryngeal and articulatory speech components are not under prominent dopaminergic control in PD. Treatment regimens should focus on nondopaminergic pharmacology and other therapies.

Key words: Central dopaminergic stimulation—Apomorphine—Speech—PD

This article has been cited by other articles:

				X. Feng, V. M. Henriquez, J. R. Walters, and C. L. Ludlow Effects of Dopamine D1 and D2 Receptor Antagonists on Laryngeal Neurophysiology in the Rat J Neurophysiol, August 1, 2009; 102(2): 1193 - 1205. [Abstract] [Full Text] [PDF]

				F Klostermann, F Ehlen, J Vesper, K Nubel, M Gross, F Marzinzik, G Curio, and T Sappok Effects of subthalamic deep brain stimulation on dysarthrophonia in Parkinson's disease J. Neurol. Neurosurg. Psychiatry, May 1, 2008; 79(5): 522 - 529. [Abstract] [Full Text] [PDF]

				M. Stacy Apomorphine: North American clinical experience Neurology, March 23, 2004; 62(6_suppl_4): S18 - S21. [Abstract] [Full Text]